Opportunity Information: Apply for PAR 16 115
Apply for PAR 16 115
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.855, 93.856,.
- This funding opportunity was created on Feb 25, 2016 and posted on Feb 25, 2016.
- Applicants must submit their applications by Jan 09, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir (R01)" (Funding Opportunity Number PAR 16-115) is a discretionary NIH research grant that focuses on improving monoclonal antibodies, or engineered antibody-based derivatives, for a very specific HIV cure-related goal: identifying and eliminating the cells that make up the persistent HIV reservoir. Even when HIV is well controlled with antiretroviral therapy, a reservoir of infected cells can remain hidden and capable of restarting infection if treatment stops. This FOA is aimed at advancing antibody-based strategies that can recognize those reservoir cells and help remove them, supporting progress toward long-term remission or eradication approaches.
The funding mechanism is an R01, meaning it is structured for substantial, hypothesis-driven research projects that can include iterative optimization, preclinical development work, and rigorous experimental validation. The activity area is categorized under health, and the opportunity is administered by the U.S. Department of Health and Human Services through the National Institutes of Health (listed as HHS-NIH11). The opportunity is associated with CFDA numbers 93.242, 93.855, and 93.856, which correspond to NIH program areas relevant to HIV/AIDS and immunology-related research support.
The eligible applicant pool is broad and includes many kinds of organizations that can carry out biomedical research. Public-sector entities such as state, county, and city governments are eligible, along with special district governments and independent school districts. Academic institutions are clearly included, covering both public/state-controlled and private institutions of higher education. Tribal eligibility is also broad, including federally recognized Native American tribal governments as well as tribal organizations that are not federally recognized, and it also includes public housing authorities and Indian housing authorities. The FOA also allows nonprofit organizations with or without 501(c)(3) status (as long as they are not institutions of higher education in those categories), for-profit organizations (other than small businesses), and small businesses. An additional catch-all category indicates that other applicants may be eligible depending on clarifications contained in the full eligibility text.
In terms of timing, the opportunity was created and posted on February 25, 2016, with an original and current closing date of January 9, 2019. The source data does not list an award ceiling or the expected number of awards, so those details are either unspecified in the summary record or were provided elsewhere in the full announcement. Overall, the FOA is designed to spur research teams to refine antibody constructs and antibody-like tools so they can better find and destroy HIV reservoir cells, addressing one of the central biological obstacles to curing HIV.
FAQs: Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir (R01) (PAR 16-115)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir (R01)" and the Funding Opportunity Number is PAR 16-115.
Which agency administers this grant opportunity?
This is a U.S. Department of Health and Human Services opportunity administered through the National Institutes of Health (NIH), listed as HHS-NIH11.
What type of grant mechanism is being used?
The funding mechanism is an NIH R01 research project grant. R01s are generally designed for substantial, hypothesis-driven research projects and can support iterative optimization, preclinical development work, and rigorous experimental validation.
What is the main scientific goal of this funding opportunity?
The FOA focuses on improving monoclonal antibodies (or engineered antibody-based derivatives) for a specific HIV cure-related objective: identifying and eliminating the cells that make up the persistent HIV reservoir.
Why is the HIV reservoir a focus if antiretroviral therapy controls HIV?
Even when HIV is well controlled with antiretroviral therapy, a reservoir of infected cells can remain hidden and capable of restarting infection if treatment stops. This opportunity targets strategies intended to recognize those reservoir cells and help remove them.
What kinds of approaches does the FOA emphasize?
It emphasizes antibody-based strategies, including monoclonal antibodies and engineered antibody-based derivatives, that can better recognize HIV reservoir cells and support their elimination.
How does this FOA relate to HIV cure research?
The FOA is aligned with progress toward long-term remission or eradication approaches by supporting research meant to refine antibody constructs and antibody-like tools to find and destroy HIV reservoir cells, a central biological obstacle to curing HIV.
What is the activity area for this opportunity?
The activity area is categorized under health.
Which CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.242, 93.855, and 93.856, corresponding to NIH program areas relevant to HIV/AIDS and immunology-related research support.
Who is eligible to apply?
The eligible applicant pool is broad and includes many types of organizations able to conduct biomedical research.
Are state, county, or city governments eligible applicants?
Yes. Public-sector entities such as state, county, and city governments are eligible.
Are special district governments and independent school districts eligible?
Yes. Special district governments and independent school districts are listed as eligible.
Are colleges and universities eligible to apply?
Yes. Academic institutions are included, covering both public/state-controlled institutions of higher education and private institutions of higher education.
Are tribal governments eligible?
Yes. Eligibility includes federally recognized Native American tribal governments.
Are tribal organizations that are not federally recognized eligible?
Yes. Tribal organizations that are not federally recognized are also included as eligible applicants.
Are public housing authorities or Indian housing authorities eligible?
Yes. Public housing authorities and Indian housing authorities are included in the eligible applicant categories.
Are nonprofit organizations eligible, and do they need 501(c)(3) status?
Nonprofit organizations with or without 501(c)(3) status are eligible, as long as they are not institutions of higher education in those nonprofit categories.
Are for-profit organizations eligible?
Yes. For-profit organizations are eligible, other than small businesses (which are separately listed).
Are small businesses eligible?
Yes. Small businesses are explicitly included among eligible applicants.
Does the eligibility list include any "other" or catch-all category?
Yes. The FOA includes an additional catch-all category indicating that other applicants may be eligible depending on clarifications contained in the full eligibility text.
When was this opportunity posted?
The opportunity was created and posted on February 25, 2016.
What was the closing date for applications?
The original and current closing date listed is January 9, 2019.
Is the award ceiling provided in the summary information?
No. The source data does not list an award ceiling, so that detail is unspecified in the summary record or may have been provided elsewhere in the full announcement.
Is the expected number of awards provided?
No. The source data does not list the expected number of awards, so it is unspecified in the summary record or may have been provided elsewhere in the full announcement.
What problem is this FOA trying to solve in practical terms?
In practical terms, the FOA aims to spur research teams to optimize antibodies or antibody-like tools so they can more effectively find and destroy cells that persistently harbor HIV, addressing a key barrier to durable remission or eradication.
Browse more opportunities from the same category: Health
Next opportunity: Combatting Slavery in Mauritania, Mali, and Senegal
Previous opportunity: Invasive Plant Intern
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 115
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 115) also looked into and applied for these:
| Funding Opportunity |
|---|
| Addiction Technology Transfer Center: Networking Coordinating Office for Internationally-based Addiction Technology Transfer Centers (Short Title: Global-ATTC) Apply for TI 16 015 Funding Number: TI 16 015 Agency: HHS-SAMHS Category: Health Funding Amount: $100,000 |
| Small Vessel Vascular Contributions to Cognitive Impairment and Dementia (VCID) Biomarkers Consortium: Coordinating Center (U24) Apply for RFA NS 16 019 Funding Number: RFA NS 16 019 Agency: HHS-NIH11 Category: Health Funding Amount: $750,000 |
| Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy Apply for CDC RFA DP14 140703CONT16 Funding Number: CDC RFA DP14 140703CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Defeat Malaria Apply for RFA 482 16 000001 Funding Number: RFA 482 16 000001 Agency: USAID-BMA Category: Health Funding Amount: $32,000,000 |
| Improving Response to and Programming in Humanitarian Emergencies Apply for CDC RFA GH15 162302CONT16 Funding Number: CDC RFA GH15 162302CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Pragmatic Strategies for Assessing Psychotherapy Quality in Practice (R01) Apply for RFA MH 17 500 Funding Number: RFA MH 17 500 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Small Vessel Vascular Contributions to Cognitive Impairment and Dementia (VCID) Biomarkers Development Projects (UH2/UH3) Apply for RFA NS 16 020 Funding Number: RFA NS 16 020 Agency: HHS-NIH11 Category: Health Funding Amount: $750,000 |
| Partner Support for Heart Disease and Stroke Prevention Apply for CDC RFA DP15 150402CONT16 Funding Number: CDC RFA DP15 150402CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| National Public Health Practice and Resource Centers for Children with Attention Deficit/Hyperactivity Disorder or Tourette Syndrome Apply for CDC RFA DD15 150502CONT16 Funding Number: CDC RFA DD15 150502CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Strategic Approaches to Improving Access to Quality Health Care for Children and Youth with Epilepsy Apply for HRSA 16 055 Funding Number: HRSA 16 055 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Developing professional training programs to increase capacity for effective global health response to humanitarian emergencies Apply for CDC RFA GH15 162402CONT16 Funding Number: CDC RFA GH15 162402CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Programs to Reduce Obesity in High Obesity Areas Apply for CDC RFA DP14 141603CONT16 Funding Number: CDC RFA DP14 141603CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| PPHF 2016: Office of Smoking and Health – Public Health Approaches for Ensuring Quitline Capacity – Financed solely by 2016 Prevention and Public Health Funds Apply for CDC RFA DP14 141003CONTPPHF16 Funding Number: CDC RFA DP14 141003CONTPPHF16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Targeted Capacity Expansion HIV: Substance Use Disorder Treatment for Racial/Ethnic Minority Women at High Risk for HIV/AIDS (Short Title: TCE-HIV: Minority Women) Apply for TI 16 011 Funding Number: TI 16 011 Agency: HHS-SAMHS-SAMHSA Category: Health Funding Amount: $500,000 |
| PPHF 2016: National Early Child Care Collaboratives - Early Care and Education Statewide Collaboratives to Improve Nutrition, Breastfeeding Support, Physical Activity and Screen Time Practices for Obesity Prevention in Young Children Apply for CDC RFA DP12 121505CONTPPHF16 Funding Number: CDC RFA DP12 121505CONTPPHF16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Early Childhood Comprehensive Systems Collaborative Improvement and Innovation Network Coordination Center (ECCS CoIIN CC) Apply for HRSA 16 179 Funding Number: HRSA 16 179 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Development, Maintenance and Enhancement of Early Hearing Detection and Intervention Information System (EHDI-IS) Surveillance Programs Apply for CDC RFA DD16 1604 Funding Number: CDC RFA DD16 1604 Agency: HHS-CDC-NCBDDD Category: Health Funding Amount: $175,000 |
| Pediatric Environmental Health Specialty Unit (PEHSU) Program Apply for CDC RFA TS14 140203CONT16 Funding Number: CDC RFA TS14 140203CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Service Area Competition – Additional Area (SAC-AA) – Tacoma, Washington Apply for HRSA 16 184 Funding Number: HRSA 16 184 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Serve as the U.S. Partner within the global STOP TB Partnership and participate in STOP TB Partnership activities Apply for CDC RFA PS12 120805CONT16 Funding Number: CDC RFA PS12 120805CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 115", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.